Association Between Stroke Subtype and Outcomes of Edaravone Dexborneol: A Subgroup Analysis of the EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) Study
Journal of the American Heart Association · 12.11.2026
DOI: 10.1161/jaha.125.048691 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, online erschienen am 12.11.2026. Verfasst von Gaoting Ma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders Beijing China. Die Arbeit nennt 28 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
The effectiveness of edaravone dexborneol among acute ischemic stroke subtypes remains unclear. We evaluated its association with clinical outcomes by stroke subtype.
Methods
This secondary analysis of the prospective EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) study included patients with acute ischemic stroke treated at 72 Chinese stroke centers from December 2022 to October 2023. Patients were classified as having large artery atherosclerosis (LAA) or non‐LAA stroke and grouped by edaravone dexborneol use. Primary outcomes were 90‐day modified Rankin Scale (mRS) scores of 0 or 1 and 0 to 2 and ordinal mRS shift. Safety outcomes were 90‐day mortality, intracranial hemorrhage, and in‐hospital adverse events.
Results
Among 4401 patients, 1061 (24.1%) had LAA and 3340 (75.9%) had non‐LAA stroke; the median age was 65 years, and 66.8% were men. Edaravone dexborneol was associated with improved 90‐day functional outcomes in the non‐LAA group, including higher odds of achieving mRS 0 or 1 (adjusted odds ratio [aOR], 1.25 [95% CI, 1.06–1.47]), mRS 0 to 2 (aOR, 1.40 [95% CI, 1.15–1.71]), and a favorable mRS shift (aOR, 1.28 [95% CI, 1.12–1.46]; all P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders Beijing China.
- Department of Neurology Yutian County Hospital of Traditional Chinese Medicine, Yutian County Tangshan Hebei Province China.
- Department of Neurology Affiliated Hospital of Jiaxing University Jiaxing Zhejiang China.
- Department of Neuroscience Dharmais Cancer Hospital-National Cancer Center Jakarta Indonesia.
- Clinical Research Unit, Dharmais Cancer Hospital-National Cancer Center Jakarta Indonesia.
- Department of Neurology Radiology Boston Medical Center Boston MA USA.
ORCID-Profile: Gaoting Ma, Raynald, Muhammad Firdaus, Yingting Zuo, Thanh N Nguyen, Qian Zhang
Zitieren
APA
Ma, G., Song, Z., Hu, J., Raynald, Firdaus, M., Wang, J., Qiu, J., Shao, Y., Xu, J., Pan, J., Zuo, Y., Nguyen, T. N., Zhang, Q., & EXPAND investigators (2026). Association Between Stroke Subtype and Outcomes of Edaravone Dexborneol: A Subgroup Analysis of the EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.048691
Vancouver
Ma G, Song Z, Hu J, Raynald, Firdaus M, Wang J, et al. Association Between Stroke Subtype and Outcomes of Edaravone Dexborneol: A Subgroup Analysis of the EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) Study. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.048691
BibTeX
@article{Ma2026,
author = {Ma, Gaoting and Song, Zhiwei and Hu, Jin and Raynald and Firdaus, Muhammad and Wang, Jianchao and Qiu, Jichao and Shao, Yanfei and Xu, Junjie and Pan, Jie and Zuo, Yingting and Nguyen, Thanh N and Zhang, Qian and EXPAND investigators, EXPAND investigators},
title = {Association Between Stroke Subtype and Outcomes of Edaravone Dexborneol: A Subgroup Analysis of the EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) Study},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.048691}
}
EUVIMED